Swissmedic Initiates Batch Recall of Verkazia Augentropfen Emulsion
Swissmedic, the Swiss agency for therapeutic products, has initiated a batch recall of Verkazia Augentropfen Emulsion, a medicinal product used for the treatment of eye conditions. The recall affects batch number 4T98H, which was distributed to healthcare professionals and pharmacies across Switzerland.
Navigation: What Changed? | Who is Affected? | What Should be Done? | Conclusion | Disclaimer
What Changed?
The recall was initiated due to quality issues with batch number 4T98H of Verkazia Augentropfen Emulsion. Swissmedic has determined that the batch does not meet the required standards for quality and safety.
Reasons for Recall
The reasons for the recall include:
- Non-conformities in the manufacturing process
- Failures in quality control measures
- Insufficient documentation of production processes
Who is Affected?
The recall affects healthcare professionals, pharmacies, and patients who have received batch number 4T98H of Verkazia Augentropfen Emulsion.
Affected Parties
The following parties are affected by the recall:
- Healthcare professionals who prescribed or administered the affected batch
- Pharmacies that dispensed the affected batch
- Patients who received the affected batch
What Should be Done?
Affected parties should take immediate action to ensure patient safety and prevent further distribution of the affected batch.
Recommended Actions
The following actions are recommended:
- Healthcare professionals should notify patients who received the affected batch and provide alternative treatment options
- Pharmacies should remove the affected batch from stock and return it to the manufacturer
- Patients who received the affected batch should contact their healthcare professional for further guidance
Conclusion
The recall of batch number 4T98H of Verkazia Augentropfen Emulsion is a critical measure to ensure patient safety and prevent further harm. Affected parties must take immediate action to comply with the recall and prevent further distribution of the affected batch.
Disclaimer
This article is for informational purposes only and should not be considered as legal or medical advice. Affected parties should consult with their healthcare professional or legal counsel for guidance on the recall and any related matters.
For full information about the Swissmedic announcement, see the link below.